CLINICAL EVENTS CALENDAR
Non-Accredited Education
 CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE On Demand Web ArchiveNon-Accredited Target Audience: Physicians, nurses, and technologists. This activity is supported by an educational grant from Terumo Medical Corporation. |
Invasive Cardiology News Wire
Catheter Repair of Leaky Mitral Valve Alternative to Surgery
In EVEREST II, the MitraClip shows superior safety, similar effectiveness
ACC 2010, Atlanta, Georgia. A catheter-mounted device that acts like a clothespin to clip together the flaps of a leaky heart valve is a safe and effective alternative to open-chest surgery in selected patients with mitral regurgitation, according to research presented today at the American College of Cardiology’s 59th annual scientific session. ACC.10 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists to further advances in cardiovascular medicine.
Boston Scientific Completes Enrollment in PLATINUM Trials for Small Vessels and Long Lesions
Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System
Boston Scientific Corporation (Natick, Massachusetts) announced at the 2010 ACC in Atlanta the completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program. The trials are designed to compare the platinum chromium PROMUS® Element™ Everolimus-Eluting Stent System to matched historical control groups of patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System. The Small Vessel trial enrolled 94 patients with de novo lesions greater than or equal to 2.25 to less than 2.50 mm in diameter and less than or equal to 28 mm in length. The Long Lesion trial enrolled 102 patients with de novo lesions greater than 24 to less than or equal to 34 mm in length and greater than or equal to 2.50 to less than or equal to 4.25 mm in diameter. Both trials enrolled patients at more than 30 sites worldwide.
Rheolytic Thrombectomy Before Stenting Found Superior to Stenting Alone in Patients with AMI
JETSTENT study finds combination treatment leads to better reperfusion, fewer adverse events
ACC 2010, Atlanta, Georgia. Conducting rheolytic thrombectomy before direct infarct-related artery stenting in patients with acute ST-segment elevation heart attack produced better clinical results than performing direct stenting alone, according to research presented today at the American College of Cardiology’s 59th annual scientific session. ACC.10 is the premier cardiovascular medical meeting, bringing together cardiologists and cardiovascular specialists to further advances in cardiovascular medicine.
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
New Data From Second Phase Shows No Blood Clots, No Repeat Procedures and Very Low MACE in Patients Treated with Abbott’s Innovative Device
ACC 2010, Atlanta, Georgia – Abbott announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE1 rate of 2.0 percent) at 30 days. These results build on the long-term success Abbott has seen with the BVS technology in the first phase of the ABSORB trial, which has generated positive data on 30 patients out to three years. Data from the second phase of the trial was presented at the American College of Cardiology's 59th annual scientific session in Atlanta.
Study Shows Superior Efficacy for TAXUS® Express® Stents at 1 Year vs. BMS in Diabetics Experiencing MI
Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberté® Stents in AMI patients
Extended Use of Dual Antiplatelet Therapy Not Effective
Dual antiplatelet therapy no more effective than aspirin-only therapy for long-term treatment
ACC 2010, Atlanta, Georgia. Coronary patients should not continue dual antiplatelet therapy 1 year after receiving a drug-eluting stent, according to research presented at the American College of Cardiology’s 59th annual scientific session.
The optimal duration of dual antiplatelet therapy administration following drug-eluting stent implantation had not previously been determined.
For this study, patients either continued to receive clopidogrel 12 months after drug-eluting stent implantation or discontinued the medication. A total of 2,701 patients, who had had no major complications in the year since receiving drug-eluting stents, were randomized to the clopidogrel discontinuation group (1,344 patients) or the clopidogrel continuation group (1,357 patients).
US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)
February 9, 2010 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥ 2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.
Cardiology Blogs
All Subscriptions are FREE to qualified cardiology professionals
- Subscribe to:
- Journal
- Digital Journal
- E-News
- RSS feed
Anytown, California
Press Release
— Bethlehem, Pennsylvania – Invatec received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October to market its Mo.Ma Ultra Proximal Cerebral Protection Device for use during carotid artery stenting (CAS). The device effectively reduces and captures debris released during the stenting procedure to prevent it from traveling to the brain, where it has the potential to cause a stroke.
CME Showcase
 The Use of Remote Robotic Navigation in Complex Arrhythmias Complimentary Accredited Web Archive This activity is designed for electrophysiologists and EP allied professionals. Diagnosing Coronary Artery Disease: Advanced Cardiovascular Imaging Solutions  New Standards of Care for CRMD Antibiotic Protection Complimentary CME Accredited Webcast Dates: November 18, 2008 Time: 6:00 pm ET November 19, 2008 Time: 3:00 pm ET This activity is sponsored by the North American Center for Continuing Medical Education. |
REVIEW OUR OTHER
CARDIOLOGY BRANDS Check out our other resources for healthcare professionals of all specialties.
Can a beta blocker before surgery reduce heart attacks? At what dosage? Clinical studies unclear, according to U-M commentary
Future studies using universal methods may give physicians clear answers about who should get beta blockers and at what dosage
FEB. 9, 2010 - ANN ARBOR, MICH. – In a commentary appearing in this week’s Journal of the American Medical Association, heart specialists at the University of Michigan Health System make a plea for clarity on the best approach for prescribing beta blockers before surgery.
It’s not unusual for patients to suffer a cardiac event during surgery, and in theory, beta blockers will reduce the risk by slowing the heartbeat, reducing blood vessel constriction, lowering demand of the heart muscle for oxygen, and generally relieving stress on the heart. However, a one-size-fits-all approach for prescribing beta blockers can harm patients at low-risk for having a heart attack.